Home Covid Nutrition Mental health Fitness Familly and pregnancy Sleep

Wegovy: Obesity treatment drug also ideal for diabetes and heart-related challanges

Author Avatar
By Erika John - - 5 Mins Read
A medical official holding up a Wegovy injection needle
Featured | Tobias Arhelger / Shutterstock

Recent research has shown that the Wegovy weight loss medication is not just an ordinary weight loss drug; it also has the potential to treat diabetes and other heart-related ailments.

By using Wegovy weight loss medication, people can indirectly safeguard themselves against diabetes and other heart issues, as it serves as a curative measure.

The researchers have recently shared some promising results that confirm the effectiveness of Wegovy weight loss drugs in helping people with obesity, type 2 diabetes, and heart failure.

This health condition occurs when the heart functions properly but is unable to pump effectively, leading to organs becoming too severe to fill properly.

Such patients have limited opportunities to engage in daily life activities, as they become easily fatigued and experience breathing difficulties, putting them at high risk of death or disabilities.

According to details of the research published in the New England Journal of Medicine616 people with Type 2 diabetes and heart failure with a preserved fraction of ejection were divided into two groups.

The participants were selected from 16 different countries and had a body mass of 30 or more.

One group received Wegovy, while the other received a placebo, and both groups were monitored for a year.

The patients who were administered Wegovy began with a lower dose and gradually increased it to 2.4 milligrams per week.

The results were remarkable. They experienced a substantial reduction in heart failure symptoms and physical limitations. Additionally, they were able to walk long distances for over six minutes, which is a significant improvement.

While ten people died in the placebo group, only six died in the Wegovy group.

The placebo group reported 88 serious detrimental events, whereas the Wegovy group reported 55.

Out of ten deaths in the placebo group, four were related to heart problems, while only one in the Wegovy group was attributed to heart issues.

Also read: Healthy snacking: Eating nuts and seeds can decrease risk of heart disease by 20%


After the research, one commonly asked question was if any of the patients were open to any risk from Wegovy side effects.

Dr Sonal Chaudhy, a professor of Endocrinology, says, "Wegovy side effects are in long-term usage, which means that patients can regain some or most of their weight if they stop using Weight loss drugs."

The deputy president of the research, Dr Mikhail Kosiborod, a Cardiologist at the Kansas City Saint Luke's Health Systems, spoke about the difficulty encountered in the research.

"I think the results from the research clearly show that while weight loss is a crucial factor, it can not clarify the whole situation," he said.

He added, "It has been awesome and helpful because the patients are difficult to treat and the number increases daily. We had very little or nothing to help them by wegovy weight loss is great news for both patients and doctors taking care of them."

Wegovy, a drug used to treat obesity, received approval from the U.S. Food and Drugs Administration in 2021.

Later, in March, it was also cleared to treat heart problems and reduce the risk of cardiovascular death. Additionally, Wegovy has been found to be beneficial for people with diabetes.